08:00 , Dec 19, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HIV/AIDS Cleavage and polyadenylation specific factor 6 (CPSF6); cyclophilin A (CYPA; PPIA) Cell culture studies...
08:00 , Jan 20, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HIV/AIDS HIV capsid protein In vitro studies identified HIV capsid protein...
08:00 , Dec 14, 2009 |  BC Week In Review  |  Clinical News

Bevirimat dimeglumine: Phase IIb started

Myriad began an open-label Phase IIb trial to evaluate 300 or 400 mg of oral MPC-4326 given twice daily in combination with antiretroviral (ARV) therapy in 300 HIV-1 patients demonstrating ARV resistance. Myriad Pharmaceuticals Inc....
07:00 , Oct 12, 2009 |  BC Week In Review  |  Clinical News

Bevirimat dimeglumine: Phase II data

A retrospective analysis of 2 Phase II trials evaluating bevirimat in 100 patients with HIV-1 infection showed that a companion diagnostic based on 5 key amino acids in HIV gag polyprotein correctly predicted 43...
07:00 , Oct 5, 2009 |  BC Week In Review  |  Clinical News

Bevirimat dimeglumine: Phase IIa data

The open-label Phase IIa 206 trial in 33 evaluable patients showed that food had minimal effect on MPC-4326 exposure. Patients received 300 or 400 mg once-daily or 100 mg twice-daily oral MPC-4326 for 15 days...
07:00 , May 7, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease ...
08:00 , Dec 8, 2008 |  BC Week In Review  |  Company News

University of Utah other research news

University research published in Science details the structure of the major homology region (MHR) of the HIV capsid protein. MHR, a region of 20 amino acids, is conserved in all retroviruses and is required...
08:00 , Nov 3, 2008 |  BC Week In Review  |  Clinical News

Bevirimat: Additional Phase IIb data

Additional data from the dose-escalation, double-blind, U.S. Phase IIb Study 203 extension, showed that 14 days of treatment with bevirimat produced a mean reduction in viral load of 1.18 log10 copies/mL in 31 patients who...
08:00 , Nov 3, 2008 |  BC Week In Review  |  Clinical News

Bevirimat: Phase IIb data

An Australian Phase IIb (Study 204) trial in 32 patients with HIV showed that bevirimat met the primary endpoint of demonstrating bevirimat plasma levels to be well above 20 µg/mL, which is the previously identified...
07:00 , Oct 13, 2008 |  BC Week In Review  |  Clinical News

Bevirimat tablet: Phase I data

In a Phase I study (Study 114) in 28 healthy volunteers, the tablet formulation of bevirimat showed good bioavailability compared to the oral solution formulation and will be evaluated further in Phase II testing. Three...